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The hepatitis C virus (HCV) is able to persist as a chronic infection, which can lead to cirrhosis and liver cancer. There is evidence
that clearance ofHCV is linked to strong responses byCD8 cytotoxic T lymphocytes (CTLs), suggesting that elicitingCTL responses
against HCV through an epitope-based vaccine could prove an effectivemeans of immunization. However, HCV genomic plasticity
as well as the polymorphisms of HLA I molecules restricting CD8 T-cell responses challenges the selection of epitopes for a widely
protective vaccine. Here, we devised an approach to overcome these limitations. From available databases, we first collected a set
of 245 HCV-specific CD8 T-cell epitopes, all known to be targeted in the course of a natural infection in humans. After a sequence
variability analysis, we next identified 17 highly invariant epitopes. Subsequently, we predicted the epitope HLA I binding profiles
that determine their potential presentation and recognition. Finally, using the relevant HLA I-genetic frequencies, we identified
various epitope subsets encompassing 6 conserved HCV-specific CTL epitopes each predicted to elicit an effective T-cell response
in any individual regardless of their HLA I background. We implemented this epitope selection approach for free public use at the
EPISOPT web server.
1. Introduction
Hepatitis C virus (HCV) causes a chronic infection that
produces liver fibrosis (20% of infected individuals) which
can lead to liver failure and the development of liver carci-
nomas [1]. An estimated 170 million people (3% of the world
population) are HCV carriers. Moreover, the prevalence of
the infection and associated complications are increasing
[1]. Standard therapy against HCV consists of a combina-
tion of interferon and ribavirine. This treatment improves
symptoms and survival prognosis of patients infected with
HCV. However, 50% of patients do not respond ade-
quately, with genotype 1 being especially refractory to treat-
ment [2]. Thus, the development of alternative treatments
against HCV, including an effective vaccine, is of paramount
importance.
No vaccine is currently available for HCV infection
[3]. With the increasing discovery of new anti-HCV small
molecule drugs, some may argue that liver disease associated
with HCV will largely disappear and thus that HCV vaccine
discovery will become superfluous. However, few of the
170+ million HCV infected population will have access to
costly medications. Nor will these medicines treat all patients
with equal effectiveness.Therefore, prophylactic treatment of
HCV infection by a vaccine represents a cost effective and
efficient alternative to medicines. Intravenous drug users—
the major group suffering new HCV infections in most
locations—have an increased likelihood of reinfection and
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would thus also benefit from prophylactic treatments able to
prevent chronic HCV infection.
HCV exhibits extraordinary genetic diversity, including
at least 6 genotypes (1 (a, b, c), 2 (a, b, c), 3 (a, b), 4a, 5a,
and 6a) and 52 different subtypes [2, 4], and this represents
a major challenge for vaccine development. Work in humans
and chimpanzees (the only animal model susceptible to
HCV) shows that antibodies are not decisive in resolution
and control of HCV infection [5, 6] possibly because this
response is focused on regions of the virus envelope, which
experiences extreme sequence variability. In contrast, there is
evidence that T cells play a fundamental role in the control of
HCV infection, since viral clearance observed during acute
transient infection correlates with the activation of CD4 T
helper (Th) lymphocytes and, importantly, with a broad and
sustained response by cytotoxic CD8 T lymphocytes (CTLs)
[7, 8]. In contrast, these responses are weak and limited in
patients with chronic infection [5, 9–13]. CTLs contribute
to the containment of viral infection by eliminating viral-
infected cells and indirectly by secretion of antiviral factors
[14], while CD4 Th cells cooperate to produce cytokines
that stimulate effector functions of CTLs [15]. Together, this
suggests that the development of a vaccine against HCV
will likely rely on the induction of T-cell responses and
in particular a CTL response. It has been shown that it is
possible to induce potent and specific CTL responses when
immunizingwith adenoviral vectors encodingHCVproducts
[16] and to protect chimpanzees from HCV infection [17].
However, given the extreme mutability of HCV, it is difficult
to conceive that acquired immunity to a single HCV strain
could protect against other, clearly divergent, strains [18]
or prevent the emergence of mutants that escape immune
responses [19, 20].
CTL responses are directed against short peptides,
epitopes, presented by human leukocyte antigens (HLA I)
expressed on the cell surface of antigen presenting and target
cells. Therefore, HCV immune evasion could be avoided
by appropriate selection of conserved HCV-specific CTL
epitopes. Currently, there are hundreds of bona fide HCV-
specific CTL epitopes deposited in specialized databases.
However, HCV diversity and extreme polymorphism of
HLA I molecules restricting the CTL responses make
optimal epitope selection anything but straightforward,
particularly if our aim is developing widely protective
epitope-based vaccine. For such a task, we started with a set
of 245 HCV-specific CTL epitopes, known to be targeted
in the course of a natural infection, and sought minimal
subsets of invariant epitopes that could be basis for a
widely protective epitope-based vaccine. We found various
epitope subsets encompassing 6 conserved HCV-specific
CTL epitopes that we predicted could elicit an effective
T-cell response in any individual regardless of their HLA I
background. Here, we analyzed these results and discussed
the reason for epitope conservation. We also introduced
EPISOPT (http://imed.med.ucm.es/Tools/episopt.html), a
server that implements our approach for selecting epitope
combinations providing the largest population protection
coverage.
Table 1: HCV genotype of polyproteins used in this study.
Genotype Sequences
1 501
2 50
3 7
4 34
5 2
6 61
Unassigned∗ 29
∗Sequences could not be readily classified onto any of the 6 major gen-
otypes. Genotypes were assigned using MuLDAS (http://www.muldas
.org/MuLDAS/).
2. Materials and Methods
2.1. HCV-Specific CTL Epitopes. We used the EPIMHC [21]
and IEDB [22] databases to identify HCV-specific CTL epi-
topes. Specifically, we collected a set of 245 peptide sequences
comprising HCV-specific CTL epitopes. These peptides were
reported to stimulate the response of human CTLs elicited
in the course of a natural infection by HCV in humans and
all have nine residues. When available, we also collected the
human MHCI molecule that was determined to restrict the
CTL response against the peptide.This peptide set is provided
as Supplementary Material in Additional File S1 available
online at http://dx.doi.org/10.1155/2013/601943 and will be
also provided by the corresponding author upon writing
request.
2.2. Retrieval, Processing, and Multiple Sequence Alignment of
HCV Polyproteins. We generated a multiple sequence align-
ment (MSA) encompassing 684 entire HCV-polyproteins
using MUSCLE [23] with default settings. The HCV-
polyproteins included representatives from all HCV geno-
types (Table 1). We obtained them from the translation
feature (CDS) of HCV nucleotide records retrieved after
GenBank genomic accessions identified in the European
HCV database (EuHCVdb). To ensure working with full-
length polyproteins, we only considered translated CDS with
more than 3000 amino acid residues. The multiple sequence
alignment (MSA) is provided as supplementary material in
Additional File S1.
2.3. Generation of an HCV-Reference Sequence with the Vari-
ables Sites Masked. We generated a HCV-reference sequence
by calculating the sequence variability in the MSA of HCV-
polyproteins using the Shannon entropy [24], 𝐻, as a vari-
ability metric [25–27]. Briefly, the Shannon entropy is given
by
𝐻 = −
𝑀
∑
𝑖=1
𝑃
𝑖
log
2
𝑃
𝑖
, (1)
where 𝑃
𝑖
is the fraction of residues of amino acid type 𝑖
and 𝑀 is equal to 20, the number of amino acid types. 𝐻
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ranges from 0 (total conservation, only one amino acid type
is present at that position) to 4.322 (all 20 amino acids are
equally represented in that position).
We assigned the sequence variability, 𝐻, to the HCV-
polyprotein obtained from GenBank accession M62321 (pro-
tein id: AAA45676.1) and subsequently masked all positions
with a variability, 𝐻, greater than 0.5, ensuring that the
remaining residue positions are highly conserved [28, 29].
2.4. Prediction of Epitope Presentation byHLA I andComputa-
tion of Population Protection Coverage (PPC). CTL epitopes
are peptides presented by HLA I molecules and recog-
nized by cytotoxic CD8 T lymphocytes (CTLs). For HLA
I molecules can only present to T cells those peptides
that bind to them, we anticipated HLA I presentation of
epitomes/peptides by predicting HLA I binding. Specifically,
we used 55 HLA I-specific motif position-specific scoring
matrices (PSSMs) [30–32] to predict epitope binding to
the corresponding HLA I molecules. We considered that a
given peptide binds to specific HLA I molecule when its
binding score ranks within the top 3% percentile of the
binding scores computed for 1000 random 9mer peptides
(average amino acid composition of proteins in the SwissProt
database).
The population protection coverage (PPC) of an arbitrary
set of CTL epitopes is given by the proportion of the
population that could potentiallymount an immune response
to any of these epitopes and can be computed by knowing
the gene frequencies of the HLA I alleles that can present
the epitopes. Given the required HLA I restriction of CTL
responses, the PPC for a set of CTL epitopes matches the
proportion of the population that exhibits at least one of
the HLA I alleles that can bind and present any of those
epitopes, which corresponds to the cumulative phenotype
frequency (CPF) of the targeted HLA I alleles. In this work,
we computed CPF using the equations described elsewhere
in [26] and the HLA I allelic and haplotype frequencies
published by Cao et al. [33] for 5 major American ethnic
groups (Black, Caucasian, Hispanic, Native American, and
Asian). HLA I allele frequencies published by Cao et al. [33]
cover most common HLA-A, -B, and -C alleles; ∼ 10–20% of
all available HLA I sequences in IMGT/HLA database
[34].
2.5. Identification of Optimal Epitope Combinations with a
Given Population Protection Coverage. In order to identify
minimal sets of epitopes (optimal epitope combinations)
with a target PPC within a starting set of CD8 T-cell
epitopes, we first find the HLA Imolecules that could present
those epitopes by predicting their binding to 55 HLA I
molecules (HLA I binding profile), as indicated elsewhere
in Section 2. With the predicted HLA I binding profiles,
we can compute CPF and, hence, epitope PPC. Once we
have the epitope HLA I binding profiles, we search for
epitope combinations from the initial set of epitopes, starting
with one epitope and iteratively increasing the number of
epitopes being considering, which reach the target PPC. At
each iteration, we also computed the largest PPC that can
be reached with the number of epitopes being considered.
Because PPC vary for the 5 ethnic groups for which we
have HLA I gene allele frequencies, we seek that the tar-
get PPC is reached in each ethnic group. We made this
method available for identifying minimal set of epitope
combinations reaching a target PPC through the EPISOPT
web server. EPISOPT is implemented on an Apache Web
server running under the Mac OSX operating system. The
EPISOPT functional core consists of a PERL CGI (Common
Gateway Interface) script that handles the input, executes the
above outlinedmethods, and then assembles and displays the
results.
2.6. Other Procedures. We identified three-dimensional (3D)
structures of HCV proteins upon BLAST searches [35] with
the epitope sequences against the PDB sequence database at
NCBI (http://blast.ncbi.nlm.nih.gov/Blast.cgi). We obtained
solvent accessibility from the relevant 3D structures using
the program NACCESS [36], and we used the server MAST
(http://imed.med.ucm.es/Tools/msat.html) for mapping the
accessibility onto the 3D structures.
3. Result and Discussion
HCV vaccines could prevent chronic HCV infection, a
leading cause of both liver fibrosis and liver cancer. Unfor-
tunately, unlike hepatitis A virus (HAV) and hepatitis B
virus (HBV) [37, 38], no such HCV vaccine exists. Most
vaccines pursue the generation of long lasting immunity
mediated by neutralizing antibodies. Thus, current vaccines
for HAV and HBV are based on viral-specific recombinant
proteins eliciting such type of immunity [38, 39]. In con-
trast, immunization trials with recombinant HCV proteins
have all failed [37], likely because antibodies do not play
a key role in the control of the infection by HCV [5, 6].
Targeting the cellular arm of the adaptive immune system
residing in the T cells is surely the key for the develop-
ment of a successful HCV vaccine [7, 8], and multiple T-
cell epitope-based vaccines are particularly suitable for that
task.
HCV diversity and HLA polymorphisms are a handicap
for developing a broadly protective T-cell epitope-based
vaccine against HCV. Therefore, epitope selection is a key
step for epitope-vaccine design. Given the relevance of CTL
responses in the containment of HCV acute infection [7, 8],
in this work we sought to find invariant HCV-specific CTL
epitopes that could serve to develop approach depicted in
Figure 1.
A key feature of the approach is the use of already
discovered CTL epitopes. Previous work has yielded large
numbers of HCV-specific epitopes, which are available in
specialized databases such SYFPEITHI [40], JenPep [41], and
MHCBN [42], TEPIDAS [43], Immune Epitope database
[44], and EPIMHC [21]. In our study, we collected the HCV-
specific epitopes from the EPIMHC and Immune Epitope
databases. We sought published, annotated epitopes that
are targeted in the course of a natural HCV infection and
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EPIMHC and IEDB databases
245 CTL epitopes
17 CTL epitopes
Epitope Ct Region HLA I binding profile PPC
KTSERSQPR G CAPSID A0301 A1101 A3101 A3301 A6801 32.20%
LIFCHSKKK C HELICc A0301 A1101 A3101 A3301  A6801 32.20%
LLPRRGPRL G CAPSID A0201 A0203 A0205 A0206 C0102 28.20%
(size: 9 residues; immunogen: HCV infection)
(1) Selection of HCV-specific CTL epitopes
(2) Sequence variability filtering (H ≤ 0.5)
(enables computing PPC)
(3) Prediction of HLA I binding profiles
combinations providing a target PPC
(4) Selection of minimal epitope set
Figure 1: HCV epitope selection approach. Overview of the
approach devised to select invariantHCV-specific CTL epitopes that
could be the basis for a broadly protective epitope-based vaccine
against HCV. The approach consists of 4 basic steps: (1) selection
of epitopes from databases according to the indicated criteria.
Immunogen HCV infection means that all selected HCV epitopes
were reported to be targeted in the course of a natural infection in
humans. They are immunogenic. (2) Sequence variability filtering.
We only considered epitopes that do not contain any residue
with a variability given by Shannon entropy, 𝐻, greater than 0.5.
(3) Prediction of epitope HLA I binding profiles which enables
computation of the percentage of the population that will be able
to elicit a T-cell response against a particular epitope (PPC). (4)
Selection of subsets of epitopes that with a minimum number of
epitopes reach a target PPC.
a size of nine residues, assembling a set of 245 HCV-
specific CTL epitopes (provided as supplementarymaterial in
Additional File S1).The bases for the selection criteria are the
following. Appropriate antigen processing is a prerequisite
for HLA presentation and limits T-cell recognition [45, 46].
By considering CTL epitopes that are targeted in the course
of a natural HCV infection, we assumed that (A) antigen
processing is conserved (it will be futile to elicit a T-cell
response against an epitope that it is not processed and
available for presentation in the course of an infection with
HCV) and (B) epitope presentation and T-cell recognition
is only determined by HLA I binding. As for the size of the
epitopes, HLA I molecules bind and present peptides from 8
to 11 residues but most of them have 9 residues [30].There are
reports in the literature echoed in the databases ofmuch large
peptides, up 30 amino acids, that are capable of eliciting CD8
T-cell responses. These peptides do not represent optimal
CD8 T-cell epitopes, as they need further processing prior to
HLA I binding.
The next step in our approach (Figure 1) was the identifi-
cation of highly conserved epitopes. In order to do so, we first
carried out a variability analysis of a multiple sequence align-
ment (MSA) of HCV-polyproteins using Shannon entropy,𝐻
(details in Section 2). The MSA included HCV polyproteins
from all 6 genotypes; however, genotype 1 was the most
represented, with 501 sequences (Table 1). Subsequently, we
masked in an HCV-polyprotein reference sequence (AN:
AAA45676.1) all variable sites within the MSA with𝐻 > 0.5.
We mapped variability onto this sequence rather than the
artificial conserved sequence for two reasons: first, conserved
sequences derived upon a MSA tend to be too long and
contain stretches of amino acids not present in any real
sequence, and secondly, AAA45676.1 has long been used
as a reference sequence to design overlapping peptides and
check T-cell responses. HCV-polyprotein AAA45676.1 with
the variable sites masked is depicted in Figure 2 showing
the location of the mature proteins. We used this sequence
to discard those epitopes that have any residue, including
those flanking the C-terminus, with 𝐻 > 0.5. The residue
flanking the C-terminus of the CTL epitope is a determinant
for proteasome cleavage, and mutations in that residue can
abrogate T-cell recognition [47]. Thus, we also required that
residue to be invariant. Only 17 epitopes meet these criteria
and are shown in Table 2. That such a few peptides have all
their residues with entropy𝐻 ≤ 0.5 reflects the large genomic
plasticity of HCV.
In general, most of the invariant epitopes reside in the
CAPSID and CORE proteins of HCV. One reason for this
preferred location is that these two proteins seem to be
the most conserved. However, regardless of such conser-
vation, we recently showed that proteins located at the N-
terminus of polyproteins bear more epitopes than expected
for the size because they are preferentially translated [25]. To
find structure-function determinants for the conservation of
these particular 17 epitopes, we identified three-dimensional
structures of HCV proteins bearing the identified epitopes
(Table 2) and mapped them onto the 3D structure (Figure 3)
(see details in Section 2). We could only map 5 of the 17 con-
served epitopes: four of them, LIFCHSKKK, HSKKKCDEL,
ITYSTYGKF, and TYSTYGKFL mapped onto two different
domains of the NS3 helicase (Figures 3(a) and 3(b)), while
one, TIMAKNEVF, mapped onto the RNA polymerase of
HCV (Figure 3(c)). Note that the epitopes LIFCHSKKK and
HSKKKCDEL overlap and so the epitopes ITYSTYGKF and
TYSTYGKFL. Interestingly, all these epitopes bear a large
proportion of residues that are hydrophobic and buried
in the 3D structure (shown in blue in Figures 3(a), 3(b),
and 3(c)). The relative accessibility of each of the epitope
residues is shown in Figure 4. For example, the fragment
ITYSTYGKFL (it contains two overlapping epitopes) and
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1 M S T .PK PQ KKNKRN TNRR P .D VK FPGGGQ IVGG VY LLPRRG PR LG VRA TRK TSER SQ PRG 60 1561 V FTG LTH IDAH FLSQ TKQ .G .N ..Y L .A YQ A TVCARA .A PPPSW D .MW KC L .R LK P .L .G 1620
CAPSID
61 RRQ P IPK .R ...G R .W AQ PG YPW P LYG N EG .GW AGW LLSPRG SR P .W G P .D PRRR SRN LG 120 1621 P TP LLYR LG .V .N E ...TH P .TK .I..CM .AD LEV .TS TW V L .GG V LAA LAA YC L ..G .V 1680
CAPSID    NS4a
121 K V ID TLTCG FAD LM G Y IP .VG A P .GG .A .A LAHG VR ..EDG .N YA TG N LPG C S FS IFLLA 180 1681 V I.G R ......P ...PDR E .LY ..FD EM EEC ....P ....G ...A EQ FK .K ..G LLQ ... 1740
CORE NS4a
181 LLSC .T .P .SA ....N ....Y ..TNDC .N .S IV .E ....I.H .PG C VPC V ...N .S .CW . 240 1741 .Q A ....P .V ...W ...E .FW .KHMW N F .SG IQ Y LAG LS TLPG N PA .A S LM .F .A ..TSP 1800
E1 NS4b
241 ...P T .A ...........R .H .D ..VG .A ..C SA .YVG D .CG ...L ..Q .F ...P ..... 300 1801 L .T ..T .L .N ILGGW .A .Q .A .P .....FV ..G ..G AA .G S .G LG K V L ID ILAG YG AG V . 1860
E1 NS4b
301 .Q .CNC S .Y .G ...G HRM AW DMMM NW SP T .........R .P ........G .HW G ...G .. 360 1861 G A LVA FK .M SG E .P ..ED .VN LLPA .LSPG A LVVG VVCAA ILRRH VG P .EG A .QW M NR L I 1920
E1 NS4b
361 Y .SM ..NW AK V .....L .AG VD ..T ...G ................G ..Q ..Q L .N .NG SW 420 1921 A FA SRG NH VSP TH YVPE .DA ...V T ..LSS LT .T .LL .R LH .W I......PC ..SW L .D . 1980
NS1
421 H LN .TA LNCN .S L .TG ..A .L .Y ...FN .SG C ..R ...C .....F ..GW G .......... 480 1981 W DW .C .V L .D FK .W L ..K L .P ..PG .P F .SCQ .G Y .G .W .VDG ...T .C .CG A .I.G H VK 2040
NS1 NS5a NS5a_1a
481 ..R PYCW H Y .P ..C ....A ..VCG PVYC FTPSPVVVG TTD ..G .P TY .W G .N .TD V ..L . 540 2041 NG .M .I.G P .TC .N .W .G TFP IN ..TTG P ..P .P .PN Y ..A LW R V .A .EYVE ....G ..H 2100
NS1 NS5a_1a
541 ..R PP .G .W FG C TW M N ..G FTK .CG .PPC ......N ..L .C P TDC FRKH P .A TY ..CG SG 600 2101 YV .G .T .D ..KC PCQ VP .PE FFTE .DG VR .HR .A P .C .P ..R .EV .F .VG L .....G SQ L 2160
NS1 NS5a_1b
601 PW .TPRC .V .YPYR LW H YPC T .N ....K .RM .VGG .EHR ..AACNW TRG ..C .L .DRDR . 660 2161 PC EPEPD V .V .TSM LTD P .H ITA E .A .RR L .RG SPPS .A SSSA SQ LSA PS LKA TC T .... 2220
NS1 NS5a_C
661 ..SP LL .TTT ....LPC S F ...PA LS TG L IH LHQ N .VD VQ Y LYG ..........KW E ... 720 2221 ..D ..L ..AN LLW RQ EM G ...TR VESE .K V ..LD S F .P ...E .D ..E .S ..A E ....... 2280
NS1 NS5a_C
721 L .FL .LADAR .C .C LW ......Q .EAA LE .L ..LNAA S .A ...G ......F ...AW ..KG 780 2281 F ..A .P .W AR PD YN PP L .E .W K .P .Y .PP .V .G C .LPP ....P .PPPR .K ....L ..S .. 2340
NS5a_C
781 ...P ...Y .....W P L .LL .L .LP .RA YA .D .......G ..........TL .P .YK .... 840 2341 ..A L ..LA .R .F ...........................S ...S .SSM PP LEG EPG D PD L 2400
NS5a_C
841 ...WW .Q Y .....EA ....W .P .L ..RGG RD ..I.......P .L .F ..TK .LLA ..G P .. 900 2401 ...SW S TVS .......VVCC SM SY .W TG A L .TPC .A EE .K LP IN .LSN S L .R .HN .VY .T 2460
NS2
901 .L .......PY FVR ...L .R .C ...R ....G .Y .Q .........TG TY .Y .H L .P L ..W A 960 2461 TSR SA ..RQ KK V TFDR .Q V .D .H Y ..V LK E .K ..A S .V .A .LLS .EEAC .LTPPH SA .SK 2520
NS2
961 ..G L .D LA VA VEPV .FS .M E .K .I.W G AD TAACG D I..G LPVSAR .G ....LG PAD .... 1020 2521  .G YG AK .VR .....A ..H I.SVW .D LLED ..TP I.TT IM AKN EV FC V .P .KGG RK PAR L I 2580
NS2
1021 .GW .LLA P ITA Y .QQ TRG L .G .I.TS LTG RD .N ...G E .Q ..S T ..Q .FL .T ...G V .W T 1080 2581 V .PD LG VR VC EK .A LYD ....LP .A .M G ..YG FQ YSP .Q R V ..L ...W ..K ..PM G F .YD 2640
RNA-dependent RNA polymerase
1081 V .HG AG ..T .A ..KG P ..QM Y TN VD .D LVGW ..P .G ..S ..PC .CG ..D LY LV TR .AD V I 1140 2641 TRC FD S TV TE .D IR .E ..IYQ .C .L ...AR ..I.S LTER LY .GG P ..N S .G ..CG YRRCR 2700
Peptidase_S29 RNA-dependent RNA polymerase
1141 P .RRRG D .R ..LLSPR P .S .LKG SSGG P .LC P .G H .VG .FRAA VC TRG VAK ..D F .PVE . 1200 2701 A SG V .TTS .G N T .TC Y .KA .AAC .AA ......M LV .G DD LVV I.ES .G ..ED ...LR .FT 2760
Peptidase_S29 RNA-dependent RNA polymerase
1201 .....R SP .F .DN S .PPVVPQ ..Q V ..LHA P TG SG K S TK VPAA YA .QG YK V LV LN PSVAA 1260 2761 EAM TR YSA PPG D .P .P .YD LE L ITSC SSN VSVA .D ..G .R .YY LTRD P .TP L .RAAW E T . 2820
DEXDc RNA-dependent RNA polymerase
1261 TL .FG .YM S .A .G ..PN IR TG .R T .TTG ..ITYS TYG K FLADGG C SGG A YD IIICD ECH S 1320 2821 RH TPVN SW LG N II..A P T .W .RM ..M TH FF ..L .....L ...L ....YG ..YS ..P LD LP 2880
DEXDc
1321 .D .T ..LG IG TV LDQ A E TAG .R L .V LA TA TPPG S .T .PH .N I.E .A L ...G E IP FYG KA I 1380 2881 .II.R LHG ..A FS LH .YSP .E .NR VA ..LRK LG .PP LR .W RHRAR .VRA .L ...GG .AA . 2940
DEXDc
1381 P ...IKGG RH L IFCH SKKKCD E LA ..L ...G .NA VA .YRG .D VSV IP ..G D VVV .A TDA L 1440 2941 CG .Y LFNW A V .TK LK LTP ...A ..LD LS .W F ..G ..GG D IYH S .S .AR PR ....C LLLL . 3000
 HELICc
3011
1441 M TG .TG D FD SV IDCN ..V .Q .VD FS LD P TF .I.T .T .PQ DA VSR .Q RRG R TG RG ..G .YR 1500 3001 .G VG I.LLP .R
1501 .V ..G ER PSG .FD ..V LC E .YD .G CAW YE LTP .E T .VR LRA Y .N TPG LPVCQ DH LE FW E . 1560
Figure 2: HCV polyprotein with variable positions masked. The figure shows the amino acid sequence HCV-polyprotein (protein id;
AAA45676.1) with residues positions with a sequence variability >0.5 masked (shown as dots). We computed sequence variability from a
multiple sequence alignment of HCV polyproteins using Shannon entropy, 𝐻, and masked the variable sites on the reference sequence as
detailed in Section 2. The mature proteins that arise upon HCV-polyprotein processing are indicated.
the epitope TIMAKNEVF only contain residues that are
completely buried or semiburied and many are hydrophobic
(Figures 3 and 4). These residues form part of the protein
hydrophobic core and are key for protein stability. Therefore,
the selected epitopes are conserved as they comprise residues
involved in protein stability.
Because we aimed to set the basis for a broadly protective
epitope-based vaccine against HCV, our next move was to be
able to compute the expected population protection coverage
(PPC) of any given set of epitopes, defined as the percentage
of the population that would be able to elicit a T-cell response
against any of them.To this end,we first predicted the binding
of each conserved epitope to 55HLA Imolecules forwhichwe
have suitable predictors (details in Section 2) thus obtaining
predicted epitope HLA I binding profiles. We assumed that
any epitope that binds to a given HLA I molecule would
be presented and able to elicit a T-cell response. Under this
scenario, the HLA I binding profile of a given epitope deter-
mines its potential PPC, and we computed it using genetic
HLA I frequencies for 5 ethnic groups in the American
population [33] (see Section 2 for a detailed explanation).
In Table 2, we show the predicted HLA I binding profiles
of the 17 conserved HCV-specific epitopes. With this data,
we then aimed to identify epitope combinations reaching a
95% PPC in all five ethnic groups being considered, using
the method, described in Section 2. This method does not
guarantee any multispecificity, as it only seeks for epitope
combinations reaching a target PPC. Multispecificity is a
common scenario in the course of natural infection as any
given individual will elicit T-cell responses against at least
two or three immunodominant pathogen-specific epitopes
[49].
We found that a PPC > 80% can be reached with just
3 epitopes, LLPRRGPRL, KTSERSQPR/LIFCHSKKK (both
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Table 2: Selected conserved HCV-specific T-cell epitopes with predicted HLA I binding profiles.
Epitope Ct Region N 3D 3D-N PPC HLA I binding profile
KTSERSQPR G CAPSID 71 NA — 32.2% A0301 A1101 A3101 A3301 A6801
LIFCHSKKK C HELICc 1391 2F55|A 365–373 32.2% A0301 A1101 A3101 A3301 A6801
LLPRRGPRL G CAPSID 36 1XCQ|P — 28.2% A0201 A0203 A0205 A0206 C0102
LPGCSFSIF L CORE 169 NA — 27.8% B0702 B1502 B1508 B3501 B5301 B5401
DPRRRSRNL G CAPSID/CORE 101 NA — 26.9% B0702 B0801 B5101 B5102 B5103 B5301 B5401
GFADLMGYI P CORE 129 NA — 6.3% A0202 A0203 A0205 A6802 B3801
NLPGCSFSI F CORE 168 NA — 5.9% A0205 C0102
SFSIFLLAL L CORE 173 NA — 5.5% A2402
TYSTYGKFL A DEXDC 1292 2F55|A 266–274 5.5% A2402
ITYSTYGKF L DEXDC 1291 2F55|A 265–273 2.7% B1516 B1517 B5702 B5801
HSKKKCDEL A HELICc 1395 2F55|A 369–377 2.5% B0801
YLLPRRGPR L CAPSID 35 1XCQ|P — 1.4% A3301 A6601 A6801
GQIVGGVYL L CAPSID 28 1XCQ|P — 0.4% A0206 A0214 B1510 B4002
TIMAKNEVF C RNADP 2587 2BRK|A 137–145 0 B1513 B5702
GPRLGVRAT R CAPSID 61 NA — 0
RLGVRATRK T CAPSID 63 NA — 0
STGLIHLHQ N NS1 686 NA — 0
Epitope: amino acid sequence of the epitope; Ct: residue that flanks the C-terminal end of the epitope; Region: protein/domain in HCV polyprotein bearing
the epitope; N: position in HCV polyprotein of the epitope N-terminal residue; 3D: PDB code with 3D structure of protein encompassing the epitope; 3D-N:
location of the epitope in the 3D structure; PPC: population protection coverage; HLA I binding profile: HLA I molecules predicted to present the epitope. All
epitope residues and c-terminal flanking residues have𝐻 ≤ 0.5. PPC values equal to the lower value computed with the gene frequencies corresponding to 5
ethnic populations [33]. PDB 1XCQ|P corresponds to a peptide from HCV capsid bound to an antibody Fab; hence we do not show the location of the epitope
in the 3D structure. NA: PDB not available.
epitopes have the same HLA I binding profile), and LPGCS-
FSIF (Figure 5(a)). This is not surprising as these epitopes
seem to target 3 mayor supertypes: A2, A3, and B7 [50–52].
Note, however, that we predicted peptide binding to MHC
I molecules beyond predefined HLA I supertypes. To reach
a PPC ≥ 95% however, we found that 6 epitopes were
required. Moreover, we found that there were 15 different
6-epitope combinations, differing in at least one epitope,
providing a PPC ≥ 95%. The largest PPC reached by one
of these epitope combinations was of 97% and included
the following peptide sequences: LLPRRGPRL, GFADLMGY,
KTSERSQPR/LIFCHSKKK, SFSIFLLAL, LPGCSFSIF, and
ITYSTYGKF. All 6-epitope combinations reaching PPC ≥
95% are provided as supplementary data in Additional File
S3.All these epitopes combinations differ one fromeach other
in at least one epitope. We also analyzed what epitopes were
actually included in the resulting solutions. Of all the epitopes
in Table 2, only the first 12 were included in at least one of the
epitope combinations reaching PPC ≥ 95%, while the last
5 were never included. The frequency at which the peptides
were included in these combinations is shown in Figure 5(b)
and varied from 15 times for peptide LLPRRGPRL (it was
included in each of the epitope combinations reaching PPC ≥
95%) to only once for GQIVGGVYL.
Overall, the results shown here indicate that only a
handful of conservedHCV-specific epitopeswould be needed
to elicit CD8 T-cell responses in any individual regardless
of their genetic background. We have preliminary data
corroborating these predictions. Thus, we have consistently
detected responses on T cells from naı¨ve people primed and
expanded using dendritic cells loaded with HCV-peptide
pools representing single 6-epitope combinations of PPC ≥
95% (data not shown). However, we only analyzed the
responses in a few individuals and more experiments are
underway. It is also important to highlight that our results
only provide conserved CTL epitope solutions for a potential
epitope-based vaccine against HCV to be broadly protective.
We know that the eventual development of an epitope-
based vaccine against HCV is a complex task that will
require optimizing peptide-epitope assembling and vaccine
delivery [53]. Moreover, such vaccine will also need to
incorporate Th epitopes as well as signals/adjuvants for
alerting the innate immune system and initiate an adaptive
response.
While in this study we focused on HCV, the same
approach could easily be extended to other pathogens;
there are thousands of CTL epitopes readily available for
many other pathogens. To facilitate that end, we introduced
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Figure 3: Three-dimensional structure mapping of HCV-specific invariant CTL epitopes. HCV fragments LIFCHSKKKCDEL and
ITYSTYGKFL map onto two different regions of the 3D structure of HCV NS3 helicase (PDB: 2F55), (a) and (b), respectively. Each of these
two fragments encompasses two overlapping HCV-specific epitopes. The HCV epitope TIMAKNEVF maps onto HCV polymerase (PDB:
2BRK) (c). Residue color used in the illustrations is related to their solvent accessibility and goes from blue for buried residues to red for
accessible residues. Overlapping HCV-specific CTL epitopes are shown underlined. Solvent accessibility was calculated andmapped onto the
3D structures as indicated in Section 2. The figures were rendered using Rasmol [48].
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Figure 4: Solvent accessibility ofHCV-specific epitopes with counterpart protein 3D structures.The figure depicts a plot of the relative solvent
accessibility (%) (𝑦-axis) of each of the residues (𝑥-axis) in the HCV fragments LIFCHSKKKCDEL (a), ITYSTYGKFL (b) and TIMAKNEVF
(c). We plotted both solvent accessibility considering all atoms (squares) and just residue side chains (triangles). Solvent accessibility was
calculated from the relevant protein 3D structures using NACCESS [36].
the EPISOPT server (http://imed.med.ucm.es/Tools/episopt
.html). The EPISOPT server (Figure 6) implements the steps
in our approach consisting of predicting epitope HLA I
binding profiles and identifying minimal sets of epitopes
reaching a determined PPC. In the future, we will enhance
EPISOPT with sequence variability analyses to select invari-
ant epitopes. EPISOPT is somewhat similar to another
online tool developed by Bui et al. [54] available at http://
tools.immuneepitope.org/tools/population/iedb input. Both
tools implement a similarmethod to compute PPC. However,
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Figure 5: Analysis of HCV-specific CTL epitope set selection. (a)
The figure depicts the largest PCC that was reached by HCV-
specific CTL epitope combinations containing 3, 4, 5, and 6 epitopes
(optimal combinations). As shown, with just 3 epitopes it is possible
to reach a PPC ≥ 80% and 6 epitopes were required to reach a
PPC ≥ 95%. (b) We found 15 distinct combinations of 6 epitopes
each reaching a PPC ≥ 95% within the 17 invariant HCV-specific
CTL epitopes. In the figure, we depicted the sequence of peptides
(𝑥-axis) that were included in the mentioned epitope combinations
and the times that were included (𝑦-axis).
unlike EPISOPT, Bui et al. [54] tool requires entering the
HLA I binding profiles of epitopes as input—it does not
predict them—and it does not find epitope combinations
reaching a given PPC.We are hopeful that in time, the results
and methods derived from this work will make a significant
contribution to the design of epitope-based vaccines.
Figure 6: EPISOPT web page. The figure shows the input page of
EPISOPT. Currently, users enter a list of CTL epitope sequences and
select a target PPC and population group. On submission, EPISOPT
will findminimal epitope combinations reaching the desired PPC in
the selected population group.
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